Welcome to our dedicated page for BIOVIE SEC filings (Ticker: BIVIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BIOVIE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BIOVIE's regulatory disclosures and financial reporting.
BIOVIE INC. (BIVI) received a Schedule 13G filing reporting that Jane Street Group, LLC and its subsidiaries collectively beneficially own 441,751 shares of Class A Common Stock, representing 5.2% of the class as of August 28, 2026. All of these shares are held with shared voting and dispositive power, with no sole voting or dispositive authority reported.
BIOVIE INC. (BIVI) reported that Chief Medical Officer Joseph M. Palumbo purchased common stock. On 2026-08-28 he bought 4,843 shares of common stock in open market transactions at $2.16 per share, bringing his directly held position to 6,036 shares.
The shares were acquired in several open market trades, all executed at the same price.
BIOVIE INC. (BIVI) director Amy Suzon Chappell purchased 727 shares of Common Stock on 2026-08-28 in an open market transaction at $2.16 per share. Following this reported transaction, she directly owns 727 shares of BIOVIE INC. common stock.
BIOVIE INC. (BIVI) reported that its Chief Financial Officer, Joanne Wendy Kim, purchased 2,500 shares of common stock in an open market transaction on 2026-08-28 at a price of $2.18 per share. Following this purchase, she directly holds 3,441 shares of BIOVIE INC. common stock.
BIOVIE INC. (BIVI) reported that President & CEO Cuong V. Do purchased common stock on August 27, 2026. He bought 15,210 shares of BioVie common stock in open market transactions at a weighted average price of $2.08 per share, with trade prices ranging from $2.05 to $2.10. Following this purchase, he directly holds 16,117 common shares of BioVie.
BIOVIE INC. (BIVI) is reported to have a significant shareholder, Alta Partners LLC, which has filed a Schedule 13G indicating beneficial ownership of 687,321 shares of Class A Common Stock, all issuable upon exercise of warrants.
Alta Partners LLC reports this position as representing 8.4% of the outstanding Class A Common Stock, with sole voting and sole dispositive power over all 687,321 shares and no shared voting or dispositive power.
BioVie Inc. is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative diseases (Parkinson’s, Alzheimer’s, Long COVID) and advanced liver disease. It is conducting a primary securities offering of up to 16,025,641 shares of Common Stock, up to 16,025,641 Pre-funded Warrants, and up to 16,025,641 Common Warrants on a best efforts basis, with no minimum raise. Each share or Pre-funded Warrant is sold together with one Common Warrant, assumed at a combined price of $1.56, with Common Warrants exercisable at $1.95 for five years. Estimated net proceeds of about $22.7 million are intended for working capital, R&D and general corporate purposes. Recent SUNRISE-PD Phase 2b data in early Parkinson’s disease met prespecified biomarker and clinical endpoints, and a $13.1 million U.S. Department of War grant supports a Phase 2 Long COVID trial. Liver candidate BIV201 has FDA Fast Track and Orphan Drug status for ascites in cirrhosis.
Morgan Stanley and Morgan Stanley Smith Barney LLC report beneficial ownership of Class A common stock of BioVie Inc. They disclose aggregate beneficial ownership of 896,822 shares, representing 11.9% of the class.
The reporting persons state they have no sole voting or dispositive power, but report shared dispositive power over 896,822 shares. The Schedule 13G/A is filed on behalf of Morgan Stanley as a parent holding company and Morgan Stanley Smith Barney LLC as a broker-dealer and investment adviser, with additional details for relevant subsidiaries referenced in an exhibit.
Morgan Stanley and its subsidiary Morgan Stanley Smith Barney LLC reported beneficial ownership of 605,472 shares of BioVie Inc. Class A common stock, representing 8.0% of the class as of June 30, 2026. Both entities list 0 shares with sole voting or dispositive power. They report 1 share with shared voting power and 605,472 shares with shared dispositive power, indicating these shares are controlled jointly within Morgan Stanley’s reporting units. The filing clarifies that it reflects only securities held by specified Morgan Stanley operating units and excludes positions disaggregated under SEC Release No. 34-39538.